Table 1.
Target and achieved blood glucose and mortality outcome time point by trial
| Intervention group | Control group | ||||
|---|---|---|---|---|---|
| Study | Glucose target (mM) | Mean achieved glucose (mM) | Glucose target (mM) | Mean achieved glucose (mM) | Mortality outcome time point |
| Studies included in the more recent systematic review [2] | |||||
| Surgical ICU studies | |||||
| Van den Berghe and colleagues [21] | 4.4 to 6.1 | 5.7 | 10.0 to 11.1 | 8.5 | Hospital |
| Grey and Perdrizet [22] | 4.4 to 6.7 | 6.9 | 10.0 to 12.2 | 9.9 | Hospital |
| Bilotta and colleagues (SAH) [23] | 4.4 to 6.7 | 5.0 | < 12.2 | 8.3 | 6-month |
| He and colleagues [24] | 4.4 to 8.3 | 6.7 | 10.0 to 11.1 | 10.0 | Hospital |
| Bilotta and colleagues (TBI) [25] | 4.4 to 6.7 | 5.1 | < 12.2 | 8.2 | 6-month |
| Medical ICU studies | |||||
| Bland and colleagues [26] | 4.4 to 6.1 | 5.8 | 10.0 to 11.1 | 9.8 | 28-day |
| Van den Berghe and colleagues [27] | 4.4 to 6.1 | 6.2 | 10.0 to 11.1 | 8.5 | 90-day |
| Walters and colleagues [28] | 5.0 to 8.0 | 6.9 | ≤15.0 | 8.1 | 30-day |
| Oksanen and colleagues [29] | 4.0 to 6.0 | 5.0 | 6.0 to 8.0 | 6.4 | 30-day |
| Bruno and colleagues [30] | 5.0 to 7.2 | 7.4 | < 11.1 | 10.6 | 90-day |
| Mixed medical-surgical ICU studies | |||||
| Mitchell and colleagues [8] | 4.4 to 6.1 | 5.4 | 10.0 to 11.1 | 7.9 | Hospital |
| Azevedo and colleagues [9] | 4.4 to 6.7 | 7.4 | < 10.0 | 8.0 | ICU |
| Preiser and colleagues [11] | 4.4 to 6.1 | 6.6 | 7.8 to 10.0 | 8.2 | Hospital |
| Brunkhorst and colleagues [12] | 4.4 to 6.1 | 6.2 | 10.0 to 11.1 | 8.4 | 90-day |
| Iapichino and colleagues [13] | 4.4 to 6.1 | 6.1 | 10.0 to 11.1 | 9.1 | 90-day |
| He and colleagues [14] | 4.4 to 6.1 | 5.1 | 10.0 to 11.1 | 10.6 | ICU |
| Zhang and colleagues [15] | 4.4 to 6.1 | 6.1 | 10.0 to 11.1 | 7.7 | Hospital |
| De La Rosa and colleagues [16] | 4.4 to 6.1 | 6.5 | 10.0 to 11.1 | 8.2 | Hospital |
| Arabi and colleagues [17] | 4.4 to 6.1 | 6.4 | 10.0 to 11.1 | 9.5 | Hospital |
| Mackenzie and colleagues [18] | 4.0 to 6.0 | 7.0 | < 11.0 | 8.4 | Hospital |
| NICE-SUGAR [4] | 4.5 to 6.0 | 6.4 | < 10.0 | 8.0 | 90-day |
| Farah and colleagues [5] | 6.1 to 7.8 | 7.9 | 7.8 to 11.1 | 9.7 | 28-day |
| Yu and colleagues [7] | 4.4 to 6.1 | 5.7 | 10.0 to 11.1 | 11.1 | Hospital |
| McMullin and colleagues [10] | 5.0 to 7.0 | 7.1 | 8.0 to 10.0 | 9.4 | Hospital |
| Additional studies included only in the earlier systematic review [1] | |||||
| Surgical ICU studies | |||||
| Stecher and colleagues [32] | 4.4 to 6.1 | n/a | 7.8 to 10.0 | n/a | n/a |
| Kia and colleagues [33] | 4.2 to 6.4 | 6.0 | 10.0 to 11.1 | 8.0 | 90-day |
| Chan and colleagues [34] | 4.4 to 6.7 | 7.0 | < 11.1 | 9.3 | Hospital |
| Medical ICU studies | |||||
| Fernandez and colleagues [35] | 4.4 to 6.1 | 6.7 | < 8.3 | 11.4 | Hospital |
| Davies and colleagues [36] | 4.0 to 8.0 | 10.3 | < 10.0 | 10.7 | Hospital |
| Gray and colleagues [37] | 4.0 to 7.0 | 6.3 | < 17.0 | 6.8 | 90-day |
ICU, intensive care unit; n/a, not available; SAH, subarachnoid hemorrhage; TBI, traumatic brain injury.